Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Wegovy is the first GLP-1 treatment approved for MASH. Read more at straitstimes.com. Read more at straitstimes.com.

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

Three years after President Joe Biden signed the Inflation Reduction Act, the Trump administration has significantly reduced ...

Secretary Francisco Tiu Laurel Jr. and National Irrigation Administration (NIA) Administrator Engr. Eddie Guillen led the NIA ...

Recent social media activity has reignited dating rumors between BTS's Jungkook and aespa's Winter. , Korean, Times Now ...

Fundsmith has invested in some excellent companies, but it has struggled to decide when to sell, says Max King ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Plainsboro: Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first and ...

AI-designed antibiotics show in vivo efficacy against multidrug-resistant N. gonorrhoeae and MRSA, offering a new approach to ...